Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma

摘要

It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein.

主权项

1. A method for treating a subject that has a triple negative basal breast cancer, comprising:
selecting the subject that has triple negative basal breast cancer; and administering to the subject an effective amount of a pharmaceutical composition comprising an antibody or antigen binding fragment thereof that specifically binds chondroitin sulfate proteoglycan 4 (CSPG4), thereby treating the triple negative basal breast cancer cell in the subject.